Stockwinners Market Radar for June 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:46 EDT Lordstown Motors receives approval of first day motions in Chapter 11 case - Lordstown Motors "announced that the United States Bankruptcy Court for the District of Delaware entered orders granting approval, on an interim or final basis, of all of the Company's "first day" motions filed in its chapter 11 cases on June 27, 2023. ordstown continues to operate with significant unencumbered cash-on-hand. Additionally, the Court granted interim approval of the Company's first day employee wages and benefits motion, which enables the Company to continue paying all employee wages, salaries, and providing benefits - without interruption. The hearing for final approval of that motion is scheduled for July 27, 2023 at 9:30 a.m."

20:10 EDT Cathie Wood's ARK Investment sold 28.4K shares of Tesla today

19:30 EDT Alvotech provides regulatory update on second BLA for AVT02 - Alvotech "announced that the FDA has issued a complete response letter for Alvotech's second Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira, or adalimumab. As the second of two BLAs submitted for AVT02, this BLA contained data to support approval as a high-concentration biosimilar and additional information to support the interchangeability designation. The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded in March 2023, must be satisfactorily resolved before the application can be approved. No other deficiencies in the application were noted by the FDA. Alvotech intends to resubmit a BLA for AVT02, including data supporting an interchangeability designation, to the FDA, which would trigger a six-month review period and a new Biosimilar User Fee Act date. Due to the expected delay in the potential approval of AVT02 in the US, as a result of the communication received from the FDA, Alvotech will explore options to raise additional capital, in order to continue advancing pipeline development in the near-term. In addition to AVT02, the company is currently developing a pipeline of 7 disclosed and 3 undisclosed biosimilar candidates. The financing options which will be explored include, but are not limited to, equity financing, sale of convertible bonds or other forms of debt financing. ATP Holdings ehf., a subsidiary of Aztiq, the largest shareholder of Alvotech, has today declared its interest in providing Alvotech with up to $100 million in proceeds from potential financing."

18:28 EDT Signet Jewelers CEO sells $650K in common stock - In a regulatory filing, Signet Jewelers disclosed that its CEO Virginia Drosos sold 10K shares of common stock on June 27th in a total transaction size of $650K.

17:42 EDT VP of Walmart Rainey sells $1.3M in company shares - VP of Walmart John Rainey disclosed that he had sold 8,526 shares of company stock at $155 per share for a total transaction value of $1,321,529.

17:39 EDT Commercial Metals CEO Smith sells 50,000 common shares - In a regulatory filing, Commercial Metals chairman and CEO Barbara Smith disclosed the sale of 50,000 common shares of the company on June 27 at a price of $50.65 per share.

17:32 EDT Airbnb officer Balogh sells 5,500 shares of company stock - Officer of Airbnb Aristotle Balogh disclosed the sale of 5,500 shares of company stock at $123.71 per share between June 26 and June 27 for a total transaction amount of $680,378.

17:24 EDT PHINIA to replace El Pollo Loco in S&P 600 at open on 7/6 - BorgWarner (BWA) is spinning off PHINIA (PHIN) in a transaction expected to be completed on July 5.

17:21 EDT PHINIA to replace El Pollo Loco in S&P 500 at open on 7/6 - BorgWarner (BWA) is spinning off PHINIA (PHIN) in a transaction expected to be completed on July 5.

17:17 EDT Kornit and Amaze team for on-demand production for social media creators - Kornit Digital announced Amaze Software parent company of the Amaze, Spring, and Outfts platforms - has selected KornitX Workflow Solutions and Kornit MAX digital on-demand fabric and textile decoration technologies as the platform to deliver their vision. Combined with the Amaze Creator Commerce Platform, the companies will jointly bring the power of on-demand production and fulfillment to new and existing social media creators, enabling them to better monetize branded products.Kornit's Global Fulfillment Network helps companies like Amaze Software connect creators with high-quality garment and textile production fulfillers across the globe. The platform is backed by the KornitX workflow engine, seamlessly integrating across industry-proven Kornit MAX technology-based fabric and textile decoration systems for end-to-end production, visibility, and control. "The social commerce market is growing rapidly, but creators struggle to capitalize on delivering branded products, as typical production cannot meet the expectations of brands and consumers for greater sustainability, creativity, agility, and market reactivity. Our flexible Global Fulfillment Network and proven on-demand digital textile technologies are designed to tackle those complexities," said Ronen Samuel, Chief Executive Officer at Kornit Digital. "Combined with Amaze's significant market reach and focus on creators, we're enabling branded collections to be delivered without production limitations, wasted inventory, or minimum order requirements - connecting with fans in-market to build tomorrow's brands while driving price-competitive revenue opportunities."

17:06 EDT BlackBerry jumps nearly 7% to $5.35 after Q1 earnings beat

17:02 EDT Ashland board approves new $1B share repurchase authorization - Ashland announced that its Board of Directors has approved a new $1B evergreen share repurchase authorization. This authorization replaces the previous $500M evergreen authorization under which there was $200M remaining. Since September 30, 2022, Ashland has repurchased approximately $300M of its outstanding shares under the previous existing authorization.

16:58 EDT American Outdoor Brands jumps 8% to $8.62 after Q4 results beat estimates

16:55 EDT GMS Inc. CEO sells $2.07M in common stock - In a regulatory filing, GMS Inc. disclosed that its CEO John Turner sold 31.1K shares of common stock on June 26th in a total transaction size of $2.07M.

16:46 EDT Federal Reserve says all 23 banks tested remained above minimum requirements - The Federal Reserve Board on Wednesday released the results of its annual bank stress test, which demonstrates that large banks are well positioned to weather a severe recession and continue to lend to households and businesses even during a severe recession. The Board's stress test is one tool to help ensure that large banks can support the economy during economic downturns. The test evaluates the resilience of large banks by estimating their capital levels, losses, revenue and expenses under a single hypothetical recession and financial market shock, using banks' data as of the end of last year. All 23 banks tested remained above their minimum capital requirements during the hypothetical recession, despite total projected losses of $541 billion. Under stress, the aggregate common equity risk-based capital ratio-which provides a cushion against losses-is projected to decline by 2.3 percentage points to a minimum of 10.1 percent. This year's stress test includes a severe global recession with a 40 percent decline in commercial real estate prices, a substantial increase in office vacancies, and a 38 percent decline in house prices. The unemployment rate rises by 6.4 percentage points to a peak of 10 percent and economic output declines commensurately. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).Reference Link

16:38 EDT USD Partners signs short-term agreement with customer at Oklahoma terminal - USD Partners has entered into a three month rail-to-truck Terminalling Services Agreement with a new, third party customer at the Partnership's Stroud, Oklahoma terminal. The short-term agreement includes take-or-pay provisions with a minimum volume commitment. The customer is entering into the agreement as a trial period to test the Stroud Terminal as a destination for its waxy crude oil production out of the Uinta Basin. If the testing period is successful, it is expected that a longer-term TSA could be executed with the customer.

16:37 EDT Overstock.com acquires Bed Bath & Beyond Brand, other IP - Overstock.com "announced the consummation of its acquisition of certain intellectual property assets of the Bed Bath & Beyond banner from Bed Bath & Beyond, Inc. under a Bankruptcy Court supervised process. Overstock is hosting a conference call tomorrow, June 29, 2023 at 8.30 a.m. ET, to discuss the transaction. Within the next week, Overstock plans to re-launch the Bed Bath & Beyond domain in Canada, followed weeks later by the re-launch of a refreshed website, mobile app, and loyalty program in the United States. New and existing customers of both Overstock and Bed Bath & Beyond will experience a single online shopping destination -- bedbathandbeyond.ca in Canada and bedbathandbeyond.com in the U.S. -- for millions of quality furniture and home furnishings products available at affordable price points for every budget. The Bed Bath & Beyond assets acquired include website and domain names, trademarks, tradenames, patents, customer database, loyalty program data and other brand assets related to the Bed Bath & Beyond banner. The U.S. Bankruptcy Court for the District of New Jersey approved Overstock's winning bid at a sale hearing on June 27, 2023. The transaction excludes any asset associated with the brick & mortar business of Bed Bath & Beyond, Inc. including store leases, inventory, warehousing, and logistics infrastructure. The buybuy Baby and Harmon banners and their assets formerly operated by Bed Bath & Beyond, Inc. are also excluded from the transaction. Pursuant to Overstock's winning bid and asset purchase agreement, the Company purchased the assets for $21.5 million, funded entirely with cash on hand. As previously disclosed, the Company had $374.7 million in cash and cash equivalents at the end of March 31, 2023."

16:35 EDT IHS Holding issues statement on recent shareholder comments - IHS Holding issued the following statement in response to recent statements from MTN, Wendel and Blackwells Capital about the Company with respect to certain corporate governance matters: "The IHS Towers management team and Board of Directors have a continued track record of engaging with shareholders, listening carefully to their views and are focused on acting in the best interests of all shareholders. We note the recent comments made by certain of our shareholders and we continue engaging in shareholder dialogue."

16:33 EDT TuSimple to explore strategic alternatives for U.S.-based operations - TuSimple is evaluating strategic alternatives for its U.S. business with a goal to maximize shareholder value. The company has engaged Perella Weinberg Partners as a financial advisor to explore possible transactions for the U.S.-based portion of its business. The decision to explore strategic alternatives for the U.S. business was guided by the company's review of multiple business factors and commercial opportunities. The company does not plan to make further public comment regarding these matters until the Board of Directors has approved a specific transaction or other alternative or otherwise concluded its review of strategic alternatives.

16:31 EDT DermTech announces restructuring, will lay off roughly 15% of workforce - DermTech announced restructuring actions that are intended to prioritize the significant growth opportunities for the DermTech Melanoma Test, streamline operations, suspend pipeline programs and significantly reduce overall operating expenses. Following a detailed review of its growth opportunities and operations, DermTech is focusing substantially all of its resources on growing reimbursed DMT billable samples and expanding payer coverage. All pipeline programs will be suspended. These restructuring actions will primarily include sales, marketing and G&A functions and will result in a workforce reduction of approximately 40 employees, or approximately 15 percent of DermTech's workforce. DermTech forecasts annualized savings of between $25 million and $30 million upon completion of the restructuring plan. The Company anticipates a one-time restructuring charge of approximately $2 million in the second quarter of 2023. "After a rigorous assessment of our entire business, we've made the tough decision to realign our organizational footprint and capital deployment," said Bret Christensen, CEO, DermTech. "We are changing certain tactics to prioritize reimbursed tests and drive revenue growth, which capitalizes on our 40 percent increase in covered lives to approximately 126 million since the end of 2022. We have a great opportunity to integrate the DMT into the melanoma care pathway to improve patient outcomes. By focusing on our mission and taking these steps today, we're better positioned to lead the genomic revolution in dermatology." DermTech had cash, cash equivalents, restricted cash and short-term marketable securities of $108.4 million as of March 31, 2023. The Company believes it will have sufficient cash resources to fund its planned operations into the first quarter of 2025.

16:30 EDT Tidewater names Dick Fagerstal chairman of the board - Tidewater announced that Dick H. Fagerstal has been appointed non-executive Chairman of the Board. In addition, the Board has reduced the size of the Board from nine to eight members. Fagerstal stated, "I am honored to assume the role of Chairman of the Board of Tidewater at such an exciting time for our industry. I believe the Company is well positioned to capitalize on the increasing global offshore activity with recently closed (and pending) additions to its fleet of offshore vessels."

16:27 EDT Worthington on-track to create two, distinct companies by early calendar 2024 - "We are very well positioned heading into our new fiscal year. We have solid growth strategies and a strong balance sheet, both of which create opportunities for us regardless of economic conditions," Rose said. "We continue to make good progress on our Worthington 2024 plan, which will create two, distinct market leading companies that will generate long-term value for our shareholders, and we remain on-track to complete the separation by early calendar 2024."

16:21 EDT McCormick names Brendan Foley as CEO, effective September 1 - The Board of Directors of McCormick & Company announced the promotion of Brendan Foley to President and CEO for the company effective September 1. Foley was also elected to the Board of Directors, effective immediately. Lawrence Kurzius will continue to serve as Executive Chairman of the Board.

16:17 EDT Shapeways announces Tier 1 supplier manufacturing contracts - Shapeways announced accelerated growth within its Enterprise Manufacturing Solutions business, securing two new Tier 1 supplier contracts that will support leading automotive and transportation manufacturers. These awards support multi-year production programs resulting in more than $2.8M in annual revenue for the next seven years. "Shapeways' readiness to embrace and invest in emerging technologies and processes, tailoring solutions to meet our customers' unique needs and requirements, sets the company apart," said John Tenbusch, Sales Director, Automotive Vertical for Shapeways. "This commitment sends a clear signal to our partners that we're more than a supplier-we're a true partner sharing in their vision for production of quality, high-performance parts."

16:17 EDT IronNet discloses NYSE listing compliance notice - IronNet announced that it received a notice from the New York Stock Exchange indicating that IronNet is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended April 30, 2023 with the Securities and Exchange Commission. As previously reported by IronNet in its Notification of Late Filing on Form 12b-25, filed with the SEC on June 15, 2023, IronNet was unable to file the Form 10-Q within the prescribed period due to diversion of company resources related in part to ongoing efforts by management to raise additional capital and negotiate a potential strategic transaction for the Company.

16:12 EDT NeuroPace appoints Joel Becker CEO and board member, Favet to step down - NeuroPace announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10. Michael Favet will be stepping down as CEO and as a member of NeuroPace's Board of Directors to pursue other opportunities. He has agreed to stay on as a consultant throughout the transition."Joel brings a distinguished track record of successful commercial leadership and is highly qualified to lead NeuroPace as we move into our next phase of commercial expansion and corporate development," said Frank Fischer, Chairman of the Board of Directors of NeuroPace. "With over 25 years of diverse experience developing markets, driving growth and leading innovation in medical technologies, from product development to corporate strategy and commercial execution, Joel brings invaluable experience, skills and insight to NeuroPace at a time when we are poised to accelerate adoption of our highly differentiated commercial progress," added Mr. Fischer. "We wish Mike continued success in his future endeavors and are pleased he has agreed to stay on as consultant through the transition."

16:08 EDT Franklin Covey affirms FY23 adjusted EBITDA view of $47M-$49M - The company states: "Driven by the continued strategic strength and durability of its All Access Pass and Leader in Me membership subscriptions, which have resulted in accelerated growth over the past years, and performance through the first three quarters of fiscal 2023, the Company affirms its previously provided guidance that Adjusted EBITDA for fiscal 2023 will increase to between $47 million and $49 million in constant currency, compared with the $42.2 million in Adjusted EBITDA achieved in fiscal 2022. The Company expects to achieve this growth despite additional growth investments and continuing macroeconomic headwinds that have adversely impacted its fiscal 2023 operating results. The Company remains confident in the strength of the All Access Pass and Leader in Me membership subscriptions, which have driven Franklin Covey's growth across recent years and which are expected to drive continued growth in the future."

16:06 EDT PAVmed receives 180-day extension to regain Nasdaq compliance - PAVmed announced that it received a written notice from the Nasdaq Stock Market granting the company a 180-day extension to regain compliance with Nasdaq's $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2). The company was first notified by Nasdaq on December 29, 2022, and originally was given until June 27, 2023, to regain compliance. The company now has until December 26, 2023, to meet the requirement.

16:00 EDT United Security Bank raises quarterly dividend to 12c from 11c per share - The dividend is payable on July 24, 2023, to shareholders of record as of July 10, 2023.

14:42 EDT Siemens transfers 6.8% stake in Siemens Energy AG to Siemens pension fund - Siemens AG has transferred a 6.8% stake in Siemens Energy AG to Siemens Pension-Trust e.V. on June 28, the company announced. "As a result, Siemens AG's stake in Siemens Energy AG declines to 25.1 percent. With this move, Siemens is executing its previously announced plans to reduce its investment in Siemens Energy. By transferring the shares to Siemens Pension-Trust e.V., Siemens is strengthening its pension assets in Germany. Siemens had already indicated before the spin-off and in conjunction with the public listing of Siemens Energy that it would further reduce its investment in Siemens Energy depending on strategic and operational developments as well as the market environment," the company stated. Reference Link

13:57 EDT North American rail traffic down 2.6% for the week ending June 24 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending June 24. For this week, total U.S. weekly rail traffic was 469,453 carloads and intermodal units, down 3.2% compared with the same week last year. Total carloads for the week ending June 24 were 222,431 carloads, down 0.4% compared with the same week in 2022, while U.S. weekly intermodal volume was 247,022 containers and trailers, down 5.5% compared to 2022. North American rail volume for the week ending June 24 on 12 reporting U.S., Canadian and Mexican railroads totaled 328,426 carloads, up 1% percent compared with the same week last year, and 327,887 intermodal units, down 5.8 percent compared with last year. Total combined weekly rail traffic in North America was 656,313 carloads and intermodal units, down 2.6%. North American rail volume for the first 25 weeks of 2023 was 16,158,745 carloads and intermodal units, down 4% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) Union Pacific (UNP), Greenbrier (GBX), Trinity (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

12:35 EDT Manchester United jumps 5% after Bloomberg says Qatari group confident

12:22 EDT Puyi Inc (ADR) trading halted, volatility trading pause

12:14 EDT Nvidia doesn't see material impact to earnings from China export rules - At the Piper Sandler Webinar: Networks for AI, Nvidia CFO Colette Kress said the company is aware of reports that the Department of Commerce is considering further controls that may further restrict exports of the A800 and H800 products to China, but the company doesn't think that additional restrictions would have an immediate material impact on Nvidia's financial results given the strength of demand worldwide for its products. Kress said that over the long-term, restrictions prohibiting the sale of its data center GPUs to China would result in a "permanent loss of opportunities for the U.S. industry to compete and lead."

12:00 EDT Hudson Pacific falls -6.4% - Hudson Pacific is down -6.4%, or -29c to $4.34.

12:00 EDT Offerpad Solutions rises 20.0% - Offerpad Solutions is up 20.0%, or $2.05 to $12.28.

12:00 EDT Kaleyra rises 39.6% - Kaleyra is up 39.6%, or $1.90 to $6.70.

10:48 EDT GSK says Bellus deal to be adjusted earnings accretive from 2027 - GSK (GSK) and Bellus Health (BLU) announced GSK has completed the acquisition of Bellus. Following the anticipated regulatory approval and launch of camlipixant, the acquisition is expected to be accretive to adjusted earnings from 2027 and has the potential to deliver "significant" sales through 2031 and beyond, the companies said in a statement.

10:34 EDT Iceberg Research says Tencent's investment 'will not change a thing at Lilium' - In a recently published report, Iceberg Research notes that eVTOL-hopeful Lilium (LILM) was given a lifeline in early May after key investor Tencent (TCEHY) provided another $100M in funding, in exchange for 184.2M warrants. "Tencent has suffered heavy losses with its poor investment in Lilium and is now throwing good money after bad. This cash infusion will not solve any underlying issues," the report reads. "Lilium's liquidity remains alarmingly tight due to expected cash burn of around EUR 250M for this year. The company has around eight months of cash, based on pro-forma liquidity of EUR 170M - after Tencent's $100M injection - as of end-June. That runway would extend to 15 months with the contingent funding." Iceberg Research believes Tencent's recent investment "will not change a thing at Lilium" and as the company continues to burn cash, "shareholders should brace themselves for the inevitable prospect of further dilution, as 130M warrants are immediately exercisable under the Tencent funding agreement." In Wednesday morning trading, shares of Lilium have gained almost 9% to $1.45. Reference Link

10:13 EDT DentalInsurance.com expands relationship with MetLife - DentalInsurance.com is expanding its relationship with MetLife. MetLife's dental offerings include a range of choices to meet an individual's oral health needs and balance costs. MetLife's coverage features more than 521,000 access points in network, with negotiated fees 30-45% below the community average.

10:00 EDT Big Lots falls -5.4% - Big Lots is down -5.4%, or -49c to $8.65.

10:00 EDT ETFS Physical Palladium Shares falls -6.6% - ETFS Physical Palladium Shares is down -6.6%, or -$7.96 to $112.16.

10:00 EDT Joby Aviation rises 23.4% - Joby Aviation is up 23.4%, or $1.49 to $7.88.

09:49 EDT Booking.com launching new AI Trip Planner - Booking.com has announced its new AI Trip Planner, which will launch in beta to a selection of U.S. travelers in the company's app on June 28. Built upon the foundation of Booking.com's existing machine learning models that recommend destination and accommodation options to millions of travelers on the platform every day, the AI Trip Planner is also partially powered by large language model technology from OpenAI's ChatGPT API to create a new conversational experience for people to start their trip planning process. Travelers can ask the AI Trip Planner general travel-related questions, as well as more specific queries to support any stage of their trip planning process, including scoping out potential destinations and accommodation options, providing travel inspiration based on the individual traveler's needs and requirements, as well as creating itineraries for a particular city, country or region. Travelers can chat with the pilot AI Trip Planner to describe what they're looking for in broad or specific terms, ask questions and refine their search in real time, with new options surfaced in just a matter of seconds. The AI Trip Planner also provides travelers with a visual list of destinations and properties, including Booking.com's pricing information, with deep-links to view more details. Travelers can go back and forth between their chat with the AI Trip Planner and the Booking.com app interface as they consider options for their trip. With just a tap on any accommodation they are interested in, they can complete the reservation, as the AI Trip Planner is directly integrated into the accommodation booking experience in the Booking.com app, the company said.

09:47 EDT OneConnect falls -5.1% - OneConnect is down -5.1%, or -17c to $3.18.

09:47 EDT Joby Aviation rises 14.6% - Joby Aviation is up 14.6%, or 93c to $7.32.

09:47 EDT Kaleyra rises 40.8% - Kaleyra is up 40.8%, or $1.96 to $6.76.

09:43 EDT EdtechX Holdings Acquisition Corp II trading resumes

09:38 EDT EdtechX Holdings Acquisition Corp II trading halted, volatility trading pause

09:32 EDT KKR reaffirms commitment to acquire Circor - KKR (KKR) reaffirmed its affiliates intention to acquire Circor (CIR) and issued the following statement: "KKR is confident that its transaction to acquire CIRCOR maximizes shareholder value while minimizing regulatory, market, and industry risks. In sharp contrast to Arcline Investment Management, whose funds own a direct competitor of CIRCOR called Fairbanks Morse Defense ("FMD"), KKR believes its transaction presents no risk of antitrust delays or failure to close at the expense of CIRCOR shareholders given the lack of competitive overlap. This is particularly important in the current regulatory climate given heightened scrutiny around consolidation between competing suppliers of the Defense Industrial Base. Any transaction delays and uncertainty associated with antitrust considerations can come at a material cost to CIRCOR shareholders, including significant time value of money impact. The KKR transaction is expected to close in the fourth quarter of 2023. Any reasonable antitrust analysis indicates that a transaction with funds that control a direct competitor to CIRCOR, even if it receives regulatory approval which is by no means certain, would close no sooner than the second half of 2024. KKR and CIRCOR submitted their Hart-Scott-Rodino filings on June 20, 2023, and all other regulatory filings have been moving forward smoothly. KKR has also agreed to eliminate third party financing risk from its transaction by providing a full equity backstop of the transaction - something that few other buyers could offer and of significant value to CIRCOR's shareholders particularly in today's uncertain financing markets. Arcline's proposal, on the other hand, is contingent on obtaining debt financing, which creates meaningful uncertainty for CIRCOR's shareholders."

09:31 EDT Joby receives certificate to test first production prototype - Joby Aviation announced it has received a Special Airworthiness Certificate for the first aircraft built at its Pilot Production Line in Marina, California. Issued by the Federal Aviation Administration, the certificate allows Joby to begin flight testing of its first production prototype, the company said in a statement. "The aircraft is expected to become the first ever eVTOL aircraft to be delivered to a customer when it moves to Edwards Air Force Base in 2024 to be operated by Joby as part of the Company's Agility Prime contract with the U.S. Air Force, worth up to $131 million," Joby added. Shares of Joby Aviation are up 9% to $6.99 in early trading.

09:27 EDT Tata Communications to acquire Kaleyra for $7.25 per share, or $100M - Tata Communications announces it has entered into a definitive agreement through Tata Communications Limited to acquire Kaleyra to empower global enterprises to offer personalised experiences to their customers. Under the terms of the agreement, Tata Communications has agreed to acquire Kaleyra in a cash only transaction, at a price per share of $7.25 for a total consideration to Kaleyra shareholders of approximately $100M and the assumption of all outstanding debt. This transaction has been unanimously approved by the Boards of Directors of both Tata Communications and Kaleyra. Consummation of the deal is subject to approval by Kaleyra's stockholders, certain regulatory approvals and other customary closing conditions. Upon closing of the transaction, expected in six to nine months, Kaleyra Inc. will become a subsidiary of Tata Communications Limited.

09:18 EDT Atossa and Quantum Leap announce six patients dosed with (Z)-endoxifen - Atossa Therapeutics and Quantum Leap Healthcare Collaborative announced that six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator, or SERM, (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive, or ER+, invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit. The I-SPY 2 TRIAL is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the FDA, and the Foundation for the National Institutes of Health, or FNIH, Cancer Biomarkers Consortium. The (Z)-endoxifen treatment arm, which is expected to enroll approximately 20 patients, is part of the I-SPY 2 Endocrine Optimization Pilot Protocol, or EOP. Patients will receive 10 mg of (Z)-endoxifen daily for up to 24 weeks prior to surgery. Currently, there are 41 I-SPY 2 sites, all of which have the EOP program open.

09:18 EDT PortX announced a new partnership with MeridianLink - PortX announced a new partnership with MeridianLink. PortX has added the integration with the MeridianLink One platform in order to increase value for customers looking to transform their digital lending. MeridianLink's cloud-based solutions enable customers to build deeper relationships with consumers through data-driven, personalized experiences across the entire lending life cycle. Its scalable platforms help customers accelerate revenue growth, reduce risk, and exceed consumer expectations through seamless digital experiences. MeridianLink's partner marketplace supports hundreds of integrations for tailored innovation..."We are excited to partner with PortX and leverage their platform to bring our digital lending solutions to more FIs," said Megan Pulliam, SVP of MeridianLink's Partner Marketplace. "By combining our advanced lending capabilities with PortX's integration technology, we can provide FIs with a powerful suite of tools that unleash rapid project creation, accelerate speed-to-market, and ultimately drive digital transformation."

09:17 EDT Square announces beta launch for Square Credit Card - Square (SQ) announced the beta launch of new banking and spend management solutions for its U.S. sellers, including new credit tools and features. The Square Credit Card, running on the American Express (AXP) network, gives sellers a new tool that provides them with more spending flexibility when they need it and a rewards program that helps them reinvest back in their business. With no late fees or annual fees, the Square Credit Card features a credit limit determined by the sales a seller processes through Square. To better serve large sellers, Square is providing these businesses with loans that can be repaid on a fixed monthly schedule, rather than through daily repayments as well as the optional ability to use external data to improve loan offer size.

09:09 EDT ENGlobal granted 180-day extension by Nasdaq to regain compliance - ENGlobal had received notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, or until December 18, 2023, to regain compliance with NASDAQ's $1.00 minimum bid requirement. The notification indicated that the Company did not regain compliance during the initial 180-day grace period provided under the rule. In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), the Company is eligible for the additional grace period because it meets the initial listing requirements for the NASDAQ Capital Market, except for the bid price, and the provision of written notice to NASDAQ of ENGlobal's intention to cure the deficiency during the additional grace period by effecting a reverse stock split, if necessary. If, at any time during this additional grace period, the closing bid price of the Company's common stock is at least $1 per share for a minimum of 10 consecutive business days, NASDAQ will provide the Company with written confirmation of compliance and the matter will be closed. If the Company chooses to implement a reverse stock split, however, it must complete the split no later than 10 business days prior to the expiration of the additional grace period in order to timely regain compliance. If ENGlobal does not meet the minimum bid requirement during the additional 180-day grace period, NASDAQ will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company can request NASDAQ for a hearing to present a plan to regain compliance. This NASDAQ notification does not impact ENGlobal's listing on the NASDAQ Capital Market at this time, and the Company's common stock will continue to trade under its current symbol "ENG" during the additional 180-day compliance period.

09:07 EDT Shineco enters cooperation agreement with Kangling Medical - Shineco announced that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., signed a joint venture cooperation agreement with Yangzhou Kangling Medical, to establish a joint venture company, Shangkang Life Science and Technology. The joint venture will be formed to improve the delivery of healthcare services and medical products throughout China. The Agreement stipulates the business activities of Shangkang Life Science which encompasses research and development, and the production and sale of medical equipment and personal protective equipment. Shangkang Life Science will be jointly capitalized in the amount of $1.4M, where 51% of the capital contributed will be provided by Shineco Life Science and 49% of the capital contributed will be provided by Kangling Medical. The Agreement also addresses Shangkang Life Science's business scope, organizational structure, financial planning and accounting, governance oversight, and management and staffing.

09:06 EDT Innoviz Technologies signs LOI with LOXO - Innoviz Technologies announced that Switzerland-based LOXO, a provider of zero-emission autonomous delivery vehicles, has signed a letter of intent, or LOI, to deploy InnovizOne LiDAR units on its delivery vehicles through 2024. Innoviz's automotive-grade LiDAR, InnovizOne, is planned to be used in LOXO's zero emission, autonomous delivery vehicles, potentially allowing retailers to transport goods from local distribution hubs to end consumers in an efficient and sustainable manner. Earlier this year LOXO and Innoviz went through a successful product evaluation and testing with Innoviz's Automotive-grade LiDAR, which led to an expanded order of InnovizOne units and a signed LOI for their 2024 fleet.

09:05 EDT Cognizant and ServiceNow announce strategic partnership - Cognizant (CTSH) and ServiceNow (NOW) announced a strategic partnership to advance adoption of AI-driven automation across industries. The expanded alliance is expected to help accelerate the path toward building a $1B combined business for Cognizant and ServiceNow. Cognizant's ServiceNow Business Group will help joint clients challenged by rising costs, growing tech debt, manual processes and sub-optimal customer experiences deploy AI to help drive improvements in three key areas: Enriched operational effectiveness; Enhanced experience; and Expedited innovation.

09:04 EDT NeuroMetrix announces recent publication of two studies on DPNCheck - NeuroMetrix noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes. Ke and colleagues developed and validated an algorithm to predict progression from mild non-proliferative diabetic retinopathy to vision-threatening DR in type 2 diabetes. The study identified kidney function, insulin production and DPNCheck abnormalities as the three independent predictors of progression to vision-threatening DR. Fukuda and colleagues evaluated 323 patients with type 2 diabetes using a cross sectional design. Patients with DPNCheck determined diabetic peripheral neuropathy had significantly worse kidney function than those without, while there was no difference between patients with and without diabetic peripheral neuropathy according to traditional clinical criteria.

09:02 EDT Eloxx Pharmaceuticals KOL even discussed Phase 2 results of ELX-02 - Eloxx Pharmaceuticals highlighted its recently held key opinion leader, KOL, event discussing the significant unmet medical need of patients with Alport syndrome and presented additional topline results from its Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome. Eloxx provided topline data for 8-weeks of treatment for the third patient in the study and data after 4, and 8-weeks after end of treatment in all three patients that have completed treatment. The rapid increase in UPCR after end of treatment in one patient who achieved remission during the trial provides additional evidence of biological activity of ELX-02 in this population. As observed in prior clinical studies, ELOX-02 was well tolerated in this trial. Based on these results, Eloxx intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations. "We were delighted to bring more attention to the debilitating unmet medical needs of Alport syndrome patients during this event," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. "Further, we are extremely encouraged by the findings from our Phase 2 trial of ELOX-02 for the treatment of Alport syndrome in patients with nonsense mutations and look forward to advancing this program into a pivotal open label study, pending obtaining the necessary capital."

09:02 EDT Definitive Healthcare expands Atlas Dataset - Definitive Healthcare announced three significant enhancements to the Atlas Dataset. First, the volume of its all-payor medical claims data increased by more than 5%. The Atlas All-Payor Claims Dataset now has more ambulatory and outpatient coverage, including 40% more claims from Federally Qualified Health Centers and 10% more claims for rural health clinics and ambulatory surgery centers. In addition, the Atlas All-Payor Claims Dataset now has increased coverage for states in the western US, including nearly 20% more claims from California, South Dakota, North Dakota, Alaska, and Idaho. The Atlas Dataset also significantly expanded the volume of claims for multiple therapy areas, including a 10% increase in digestive disease-related claims. Second, Definitive Healthcare introduced the Atlas Behavioral Health Dataset. Built on intelligence from claims data, the Atlas Behavioral Health Dataset leverages AI and advanced data science to provide customers with a comprehensive view of behavioral healthcare care settings across the provider landscape. Customers can leverage the Atlas Behavioral Health Dataset to better identify, segment, and research the unique facilities and treatment locations that are part of a patient's behavioral care journey. Third, the Atlas Reference & Affiliation Dataset now contains over 1.5 million healthcare executive contacts, a 50% increase since February 2023. With expanded intelligence on executive contacts gathered and verified via proprietary methods, customers are armed with high-quality, reliable contact information on key decision-makers across the care continuum that can power their sales and marketing efforts.

09:01 EDT AvePoint expands AvePoint Certfication Program - AvePoint announced its continued investment in its channel business with the expansion of the AvePoint Certification Program and the upcoming addition of Partner Locator, which will help partners address the evolving digital collaboration security needs of their customers and drive their revenue.

08:58 EDT Abcam confirms Dr. Jonathan Milner withdrew EGM requisition, resolutions - Abcam confirmed that it has received a letter of undertaking from Dr. Jonathan Milner withdrawing his notice dated May 30 which required the Company to call an Extraordinary General Meeting of its shareholders to consider certain resolutions proposed by him..."The Abcam Board and management team appreciate the constructive discussions we have had with our shareholders and will continue to maintain an ongoing dialogue. Our Board remains focused on our recently announced process to explore strategic alternatives for the Company, which will evaluate a broad range of options to maximize shareholder value, including a potential sale of the Company," noted the statement.

08:49 EDT Red Cat's Teal Drones secures $1.2M additional funding from U.S. Army - Red Cat Holdings announces that subsidiary Teal Drones has secured an additional $1.2M to continue developing a new sUAS prototype for the U.S. Army's Short Range Reconnaissance program. Teal was first awarded a prototype contract for the SRR Tranche 2 program in March 2022, and the Army is now obligating a total of $2.7M for Teal's participation. Teal is one of only three vendors competing in Tranche 2, which the Army has advised will now be the final tranche of the SRR program. After vendors complete a series of testing and demonstration milestones, the winning vendor will be selected to produce a rucksack-portable sUAS. The system will provide Army platoons with a rapidly deployable surveillance and reconnaissance capability to gain situational awareness beyond the next terrain feature. The newly obligated funding brings additional objective requirements, originally assigned to Tranche 3, for the sUAS prototypes to meet.

08:47 EDT Thomson Reuters to acquire Imagen, terms not disclosed - Thomson Reuters signed a definitive agreement to acquire Imagen Ltd., a cloud-native media asset management company. The business will be operated as part of the Reuters News division of Thomson Reuters.

08:42 EDT American Resources receives unsolicited bid for American Carbon - American Resources has received an unsolicited bid for the assets of its wholly owned metallurgical carbon division, American Carbon, that included upfront cash, assumption of debt and a scaling royalty structure totaling an implied enterprise value of approximately $260M. The proposal was not accepted due to the duration and structure of the consideration payments, but the Company remains committed to maximizing the value for shareholders including the sale, lease or expansion of production from the company's metallurgical carbon assets. The unsolicited bid included $12M in cash over the first six months, assumption of certain debts plus a structured royalty stream of up to $260M in implied enterprise value over a twelve-year period. The company said, "Consistent with its fiduciary duties and in consultation with advisors, American Resources' Board of Directors and Strategic Committee determined that the proposal, as it its defined, is not in the best interest of American Resources' shareholders. The Board of Directors and Strategic Committee of American Resources will evaluate all options and opportunities for its American Carbon division. Additionally, the Company is continuing to pursue the spin-off of its wholly owned ReElement Technologies division and growth of its American Metals division to support the growth of the electrified economy."

08:37 EDT LiveOne joins Russell Microcap Index - LiveOne announced that it joined the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market closed on June 23, 2023. Robert Ellin, LiveOne's CEO and Chairman, commented, "Being added to the Russell Microcap Index provides us with greater visibility and stature among institutional investors and signifies the value we are creating for our shareholders. We thank our employees, partners and investors for their continued support."

08:37 EDT Coveo Solutions' AI platform earns ISO 27001 certification - Coveo has received ISO 27001 certification, highlighting its laser focus on customer security. ISO 27001 is the leading international standard focused on information security, developed to help organizations protect their information systematically and cost-effectively by adopting an Information Security Management System.

08:35 EDT Cellectar Biosciences presented data at SNMMI on study of iopofosine I 131 - Cellectar Biosciences announced it presented data at the Society of Nuclear Medicine and Molecular Imaging, SNMMI, Annual Meeting from 64 evaluable, relapsed, or refractory multiple myeloma patients in which iopofosine I 131 demonstrated an overall response rate of 28%, a clinical benefit rate of 70% and a disease control rate of 92%. The company's chief operating officer, Jarrod Longcor, presented data on a total of 72 post-5th line MM patients, of which 64 were evaluable and with 57% being classified as high risk. The oral presentation highlighted data demonstrating the outcomes from two dose levels across these highly refractory patients. The focus was on 28 patients that received the optimal dose of greater than60 mCi total administered dose. These patients were predominately either post-BCMA immunotherapy, triple-class refractory or quad-class refractory. Key data in the patients receiving greater than60 mCi TAD included: Overall response rate of 32%, Clinical benefit rate of 75%, Disease control rate of 85.7%. Key data in patient subsets that were highly refractory and received greater than60 mCi TAD included: 46% ORR in triple-class refractory patients, median PFS of 3.4 months; 50% ORR in quad-class refractory patients, PFS evaluation ongoing; 50% ORR in post BCMA relapsed or refractory patients, median PFS of 3.3 months. The most commonly observed treatment emergent adverse events were consistent with those previously reported: cytopenias including Grade 3 or 4 thrombocytopenia, anemia, neutropenia, and decreased white blood cell count.

08:35 EDT ReShape presents data on Diabetes Bloc-Stim Neuromodulation device - ReShape Lifesciences presented data on its proprietary Diabetes Bloc-Stim Neuromodulation device in an e-poster at the American Society for Metabolic and Bariatric Surgery 2023 Annual Meeting, being held in Las Vegas, NV, June 25 - 29, 2023. "Type 2 Diabetes Mellitus remains challenging to effectively treat, despite medication, surgery and diet," stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences. "ReShape's DBSN device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose. Increased glycemic control has been demonstrated in a Zucker rat model of T2DM as well as in an alloxan treated swine model of T2DM. In-vivo evidence in swine suggests that multiple applications of stimulation of the celiac branch did not cause beta cell exhaustion using the DBSN device and, with further studies, may hold significant promise to treat T2DM." In swine experiments glycemic control was assessed by applying stimulation and block for the duration of six 4-hour oral glucose tolerance tests. The total cumulative time was 24 hours which may lead to beta cell exhaustion. To test for exhaustion blood insulin was measured during an OGTT prior to and following experiments. The insulin response was quantified by calculating the area under the curve of insulin versus time. There was an apparent, but non-significant, increase in baseline insulin following stimulation and block experiments. In terms of overall response there was no significant change in AUC.

08:33 EDT Sellas Life Sciences reports data from Phase 1 study of galinpepimut-S - SELLAS Life Sciences announced topline clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S, combined with the checkpoint inhibitor nivolumab in patients with malignant pleural mesothelioma who were either refractory to or relapsed after at least one line of the standard of care therapy. Nine of the ten patients enrolled received at least three doses of GPS, with the third GPS dose given in combination with nivolumab. All enrolled patients had either received and progressed with or were refractory to frontline pemetrexed-based chemotherapy. Additional immune response data from all ten patients is expected by Q4 2023. The study details are as follows: 70.3 weeks median overall survival in patients who received the combination therapy and 54.1 weeks for all ten patients. Median overall survival for patients who entered the study as Stage IV patients was 62.3 weeks. OS was calculated as the time from cessation of the most recent previous therapy until confirmed death or most recent data update for patients who are still alive; 11.9 weeks median progression-free survival for all patients; 30% disease control rate with three patients achieving stable disease per RECIST criteria with the tumor volume decrease of up to 17%; As expected in this high-risk advanced cancer population, all patients experienced adverse events, unrelated and related. Seven out of ten patients had treatment related toxicities and six had nivolumab related toxicities. Grade 3 and higher toxicities were observed in three patients. None of the G3 and higher toxicities were related to GPS. GPS related toxicities were observed in three patients, all were Grade 1 and included G1 skin induration at the site of injection/injection site reaction and/or fatigue in two patients and G1 dizziness and non-cardiac chest pain, each in one patient. Of the ten evaluable patients, eight were male and two were female, with a median age of 69 years; All patients had MPM epithelioid and/or sarcomatoid variant, a tumor which universally expresses Wilms Tumor 1.

08:32 EDT Tata Communications agrees to acquire Kaleyra for $7.25 per share - In a notice to the National Stock Exchange of India, Tata Communications communicated that it has entered into an agreement to acquire Kaleyra, a company incorporated under the laws of the State of Delaware, United States of America, and listed on the New York Stock Exchange. "The proposed transaction is also subject to satisfactory completion of the conditions precedent as stipulated in the transaction documents, including regulatory and other approvals as may be necessary and expedient," the filing stated. "The consideration payable to the shareholders of Kaleyra Inc. is equal to $7.25 per share of Kaleyra common stock. The aggregate consideration is expected to be around $100M, as may be adjusted by any payments required to Kaleyra warrant holders or holders of restricted stock units which vest upon change of control. Additionally, Kaleyra Inc. will be acquired with a debt in its books. Kaleyra Inc. has a Gross debt of $224.9M and Net debt of $149.9M as on March 31," the notice stated. Reference Link

08:25 EDT AYRO announces 2023 AYRO Vanish enters Production Readiness Review - AYRO announced the 2023 AYRO Vanish has entered into Production Readiness Review, which assesses the readiness of a system's design and operation to enter Low-Rate Initial Production and Full-Rate Production.

08:22 EDT Brookfield Reinsurance completes filing of recast financial statements - Brookfield Reinsurance has filed recast audited consolidated financial statements as of December 31, 2022 and December 31, 2021 and for each of the three years in the period ended December 31, 2022 and corresponding management's discussion and analysis. The Recast Financial Statements have been prepared in connection with Brookfield Reinsurance's previously announced conversion of its accounting framework from International Financial Reporting Standards, as issued by the International Accounting Standards Board, to accounting principles generally accepted in the United States of America. The Recast Financial Statements supersede and replace in all respects the previously filed annual consolidated financial statements of Brookfield Reinsurance for such periods.

08:19 EDT Ovid Therapeutics appoints Zhong as CSO, Malhotra as CMO - Ovid Therapeutics (OVID) announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs. The Company also announced changes to its administrative functions intended to enhance efficiency and reduce costs. Scientific Leadership & Development Appointments: Dr. Zhong Zhong joins Ovid as Chief Scientific Officer, CSO, and Dr. Manoj Malhotra assumes role as Chief Medical Officer, CMO, following the planned retirement of Dr. Claude Nicaise. Prior to joining Ovid, Dr. Zhong served in senior leadership and scientific roles at Generation Bio (GBIO). Dr. Zhong will partner closely with Dr. Manoj Malhotra who is taking on an expanded role as Chief Medical Officer. Corporate Strategy & Leadership Appointment: In addition to deepening its bench of scientific leadership, Ovid expanded the role of Meg Alexander to the position of Chief Strategy Officer. In this remit, she will oversee Ovid's corporate strategy and planning, performance measurement, and risk mitigation. General & Administrative Infrastructure Cost Reductions & Operational Efficiencies: The Company continues to expect that its capital should fund operations into the first half of 2025. Additionally, Ovid is eligible for significant milestones and royalties if soticlestat is approved and commercialized, which would serve as a long-term and non-dilutive capital source for the Company.

08:16 EDT TransUnion appoints Venkat Achanta as chief technology, data, analytics officer - On July 1, 2023, Venkat Achanta will take on the newly expanded role of Chief Technology, Data & Analytics Officer at TransUnion. Achanta will assume leadership of the Global Technology organization in addition to the Data & Analytics organization he has led since February 2022. Along with leading a unified data strategy and data science across the organization, Achanta will be responsible for all aspects of the company's technology, including strategy, security, product engineering, operations, infrastructure and delivery of solutions that support TransUnion's global information systems. Achanta was appointed Executive Vice President, Chief Data & Analytics Officer of TransUnion in February 2022 following the completion of TransUnion's acquisition of Neustar, Inc. in December 2021. Abhi Dhar, who has been leading the Global Technology organization since 2019, recently announced his decision to leave TransUnion to pursue other opportunities. Dhar will serve as a Strategic Advisor through September 1, 2023, and will continue to serve on the Board of Directors of TransUnion CIBIL.

08:14 EDT Osisko Gold announces transaction with Hot Chili on Costa Fuego Project - Osisko Gold Royalties announces that it has entered into a binding agreement to acquire a 1.0% copper net smelter return royalty and a 3.0% gold NSR royalty from Hot Chili Limited covering Hot Chili's Costa Fuego Copper-Gold Project in Chile, for total cash consideration of $15M. Sandeep Singh, President and CEO of Osisko commented: "Costa Fuego has the potential to be a long-life, lower-cost copper mine in Chile, with significant by-product credits, importantly situated at low elevation and in close proximity to key infrastructure. We are impressed with what the Hot Chili team has been able to accomplish to date, most notably on the exploration and permitting fronts, and we look forward to future development milestones at Costa Fuego."

08:13 EDT Esperion applies for expanded indication with EMA for NILEMDO, NUSTENDI - Esperion announced that the application was filed for a Type II variation with the European Medicines Agency, EMA, for the Company's oral non-statin products marketed as NILEMDO and NUSTENDI in Europe. The application asks EMA to approve both NILEMDO and NUSTENDI to reduce cardiovascular risk in patients with or at high risk for atherosclerotic cardiovascular disease. The Type II variation application in Europe marks the culmination of Esperion's landmark Cholesterol Lowering via bempedoic acid, an ACL-Inhibiting Regimen Outcomes trial in which NILEMDO demonstrated significant cardiovascular risk reduction across a range of important clinical events including a 27% risk reduction of non-fatal myocardial infarction, a 23% risk reduction of the composite of fatal and non-fatal myocardial infarction, a 19% risk reduction of coronary revascularization, a 15% risk reduction of the MACE-3 composite, and a 13% risk reduction of the MACE-4 composite. The Company anticipates the first action from EMA in October 2023, with EMA approval in the first half of 2024.

08:11 EDT Olink announces availability of new findings on human proteome from UKB - Olink announced the availability of new findings into the variability of the human proteome, based on measurements of approximately 1,500 proteins in over 50,000 participants from the UK Biobank, UKB. In April 2023, over 50,000 samples from UKB, analyzed on the Olink platform, were released to the scientific community as the largest collection of proteomic data to date. The first addition of normal protein ranges based on the UKB data on Olink Insight contains data on approximately 1,500 proteins, while the second phase release will cover up to ~ 3,000 proteins. "The large-scale UKB cohort gives scientists a clear view into the normal variability of protein levels in humans, providing an invaluable resource guiding informed decisions in their research," said Markus Sallman Almen, Chief Data and Analytics Officer, Olink. "This release of high-quality protein biomarker data, along with proper analysis and visualization, is a major step forward in accelerating the adoption of proteomics in the research community and our understanding of the dynamic plasma proteome. We look forward to the discoveries that will come now that the UKB data is available to the wider scientific community."

08:10 EDT Aspira Women's Health receives $1M loan forgiveness, six-month payment deferral - Aspira Women's Health announced that the Connecticut Department of Economic and Community Development has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company's total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements until December 1, 2023. As a result of the loan forgiveness and deferrals, the Company expects cash outflows for the year ending December 31, 2023, to be reduced by $247,000.

08:09 EDT ADDvantage's Fulton expands operation, service offering - ADDvantage Technologies Group's Fulton Technologies is expanding its operation and value-added services to the deployment of fiber broadband connectivity. Fulton is planning to leverage much of its current infrastructure and resources to take advantage of synergies. They are also working alongside their own vast national network of vendor partners to deploy services. As the Company enters into new agreements additional details will be released and/or disclosed on their company website or via future press releases.

08:07 EDT Regional Health announces shareholder approval of special meeting proposals - Regional Health Properties convened its special meeting of the holders of its 10.875% Series A Cumulative Redeemable Preferred Shares and the holders of its common stock and Series E Redeemable Preferred Shares on June 27, 2023. All of the proposals presented at the Special Meeting were approved by the requisite votes of the applicable shareholders of the Company, including the Preferred Series A Charter Amendment Proposal, the Series B Preferred Stock Proposal and the Common Charter Amendment Proposal. As previously announced, the Company commenced an offer to exchange any and all of its outstanding shares of Series A Preferred Stock for newly issued shares of the Company's 12.5% Series B Cumulative Redeemable Preferred Shares. In exchange for each share of Series A Preferred Stock properly tendered prior to 11:59 p.m., New York City time, on June 27, 2023 and accepted by the Company, participating holders of Series A Preferred Stock will receive one share of Series B Preferred Stock. The Exchange Offer expired at the Expiration Date. All conditions to the Exchange Offer were satisfied at that time, including: the approval of the holders of at least 66 2/3% of the outstanding shares of the Series A Preferred Stock as of the close of business on May 11, 2023 of each of: the proposal presented at the Special Meeting relating to certain amendments to the Company's Amended and Restated Articles of Incorporation with respect to the Series A Preferred Stock that will significantly reduce the rights of holders of Series A Preferred Stock, as described in the Proxy Statement/Prospectus that is filed with the U.S. Securities and Exchange Commission; and the proposal presented at the Special Meeting relating to the temporary amendment of the Charter to increase the authorized number of shares of preferred stock to 6,000,000 shares and, following the consummation of the Exchange Offer, the subsequent amendment of the Charter to decrease the authorized number of shares of preferred stock to 5,000,000 shares and the authorization, creation and designation by the Board of Directors of the Company pursuant to Section 14-2-602 of the Official Code of Georgia Annotated, from the authorized but undesignated shares of preferred stock, of the Series B Preferred Stock; and the approval of a majority of votes entitled to be cast by the holders of the outstanding Common Stock and Series E Preferred Stock as of the Record Date, less any shares of Series E Preferred Stock redeemed prior to the Special Meeting, of the proposal presented at the Special Meeting relating to the Series A Charter Amendments and the temporary amendment of the Charter to increase the authorized number of shares of the Company to 61,000,000 shares, consisting of 55,000,000 shares of common stock and 6,000,000 shares of preferred stock, and, following the consummation of the Exchange Offer, the subsequent amendment of the Charter to decrease the authorized number of shares of the Company to 60,000,000 shares, consisting of 55,000,000 shares of common stock and 5,000,000 shares of preferred stock. Since the Preferred Series A Charter Amendment Proposal, the Series B Preferred Stock Proposal and the Common Charter Amendment Proposal were approved by our shareholders, we will amend the Charter to reflect the Series B Charter Amendments. In addition, since the Preferred Series A Charter Amendment Proposal and the Common Charter Amendment Proposal were approved by our shareholders, we will amend the Charter to reflect the Series A Charter Amendments upon the consummation of the Exchange Offer. Continental Stock Transfer & Trust Company, the exchange agent in connection with the Exchange Offer, has advised the Company that, as of the Expiration Date, approximately 80% of the outstanding shares of Series A Preferred Stock had been properly tendered in the Exchange Offer. The Company anticipates issuing a press release to announce the final results of the Exchange Offer. The Company intends to accept all of the shares of Series A Preferred Stock properly tendered prior to the Expiration Date. The closing of the Exchange Offer is expected to occur by June 30, 2023.

08:06 EDT Synopsys, Samsung Foundry deepen collaboration - Synopsys (SNPS) and Samsung Foundry (SSNLF) are deepening their collaboration to help chipmakers accelerate the design of 2.5D and 3D multi-die systems on Samsung's most advanced process technologies. The collaboration addresses key requirements of multi-die systems for intense computing applications including high-performance computing, AI, automotive and mobile. By providing an unmatched combination of certified EDA reference flows including Synopsys 3DIC Compiler and UCIe IP for die-to-die connectivity, mutual customers can accelerate the development of multi-die systems on Samsung Foundry's 5nm, 4nm and 3nm processes and using I-Cube and X-Cube technologies.

08:06 EDT Casey's General Stores plans store count growth, accelerate food business - Casey's General Stores announces its new three-year strategic plan. "Casey's has delivered exceptional performance over the last three years, growing our inside same-store sales by 6.5% this past fiscal year, and expanding our footprint by over 350 stores since 2020," said Casey's President and CEO Darren Rebelez. "Our new strategic plan demonstrates that Casey's is truly a category of one. F " Through its new three-year strategic plan, Casey's is building on historic strengths and articulating areas of further opportunity, focused on five key initiatives: Grow Store Count: As the nation's third largest convenience store retailer with over 2,500 stores in 16 states, Casey's will continue to grow its footprint to have the right stores in the right locations with the right products to meet guests' needs. Through organic growth and acquisitions, the company is targeting the addition of 350 stores by the end of fiscal year 2026. Accelerate the Food Business: Through an insights-driven innovation process, Casey's will elevate convenient food aligned to guest needs, providing menu options that are craveable and available only at Casey's.

08:04 EDT CBAK Energy Technology announces strategic agreement with HiNa Battery - CBAK Energy Technology announced that it has entered into strategic agreements with HiNa Battery, a unicorn and leading player in the sodium electricity industry, and Hello Tech, the parent company of Jackery, a premier global portable power supplier, respectively. In accordance with the strategic agreement between CBAK Energy and HiNa Battery, a dedicated segment of CBAK Energy's sodium-ion battery production line will be allocated for HiNa Battery's use. In return, HiNa Battery will consistently provide CBAK Energy with top-tier cathode materials that exhibit unparalleled stability within the sodium electricity industry. Similarly, under the strategic agreement with Hello Tech, Hello Tech commits to enhancing its collaborative support for CBAK Energy. In addition, during the Corporate Open Day, CBAK Energy also announced that it is the first company in the world to achieve mass production of large cylindrical sodium batteries and a full-scale commercialization along the entire value chain from upstream to downstream.

08:03 EDT Karyopharm begins Phase 3 clinical trial for selinexor with ruxolitinib - Karyopharm Therapeutics announced the initiation of a pivotal Phase 3 clinical trial to assess the efficacy and safety of once-weekly selinexor 60mg in combination with ruxolitinib in JAKi-naive patients with myelofibrosis. The randomized, double-blind, placebo-controlled study is expected to enroll 306 JAKi-naive patients with intermediate or high-risk myelofibrosis. Patients will be randomized 2:1 to ruxolitinib plus selinexor 60mg or ruxolitinib plus placebo in 28-day cycles. Ruxolitinib dose will be determined by the investigators based on the patients' baseline platelet count per the drug's prescribing information. The co-primary endpoints of the study are spleen volume response rate of greater than or equal to 35% and symptom improvement of greater than or equal to 50%at week 24, with a key secondary endpoint of anemia response at week 24. Updated data from the Phase 1 study recently presented at American Association for Cancer Research Annual Meeting 2023, American Society of Clinical Oncology 2023 and European Hematology Association 2023 showed rapid, deep and sustained spleen responses and robust symptom improvement in patients treated with selinexor 60mg in combination with ruxolitinib as of the April 10 data cut-off date. Karyopharm expects to present top-line data readout from this study in 2025. The company plans to expand its clinical development program in myelofibrosis by investigating selinexor in other front-line opportunities, such as novel combinations, to benefit the greatest number of myelofibrosis patients.

08:02 EDT Asset Entities launches AI Bot Eddie on Discord - Asset Entities has officially launched its new AI Bot "Eddie" in its new discord server. Users can ask Eddie specific questions, ask him to create or find images, as well as ask him to weigh in on any subject matter "humanly" imaginable.

08:01 EDT Avalon Holdings announces resignation of CFO Bryan Saksa and succession plan - Ronald E. Klingle, Chairman of the Board of Avalon Holdings announced that on April 26, Bryan P. Saksa resigned as CFO, Treasurer and Secretary of Avalon Holdings and from all director and officer positions of all subsidiaries of the Company. Saksa joined Avalon in December 2014 as CFO and Treasurer of the Company. Saksa was a director of the Company since April 2015 and was appointed Secretary in November 2015. Saksa's departure is not a result of any disagreement with the Avalon or its Board of Directors relating to the Company's operations, policies or practices or any issues regarding its accounting policies or practices. In addition, on April 26, Klingle announced that Avalon appointed Stefanie Villella, Corporate Controller of Avalon, to serve as interim CFO and Treasurer of Avalon. A search has been initiated to identify a new CFO and Treasurer.

07:57 EDT Blue Water Biotech announces preclinical data on use of norovirus S&P VLP - Blue Water Biotech announced preliminary preclinical data supporting the use of its norovirus shell and protrusion virus-like particle platform to develop a novel monkeypox vaccine candidate. In August 2022, Blue Water announced plans to explore the development of its novel monkeypox vaccine candidate by presenting monkeypox antigens within the S&P platform. Following successful integration of selected antigens into the platform, mice were immunized with the vaccine candidate and analyzed for antibody levels in the blood. Initial data show that mice were able to generate an immune response following vaccination and antibodies were able to neutralize the vaccinia virus. Vaccinia, the virus responsible for smallpox disease, belongs to the same family as monkeypox virus and has shown high levels of cross-reactivity with monkeypox

07:39 EDT ZyVersa Therapeutics announces publication on NLRP3 inflammasome activation - ZyVersa Therapeutics announces publication of an article in the peer-reviewed journal, Clinical Immunology, demonstrating the role of inflammasome NLRP3 activation in lupus nephritis. In the paper titled, "Renal NLRP3 Inflammasome activation is associated with disease activity in lupus nephritis," the authors evaluated renal biopsy tissue of patients with biopsy proven LN in comparison to control tissue. Data demonstrated that renal NLRP3 inflammasome activation positively correlated with LN severity and clinicopathological indices of LN. Following are key findings reported in the paper: Expression patterns of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 in the glomeruli and tubulointerstitum of LN patients were significantly higher in LN patients versus controls; Levels of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 were higher in patients with proliferative LN than in patients with non-proliferative LN; Levels of NLRP3, ASC, caspase-1, IL-1beta, and IL-18 were positively correlated with several clinicopathological indices, including, proteinuria, renal pathological activity indices, and systemic lupus erythematosus disease activity index scores. The authors stated, "We comprehensively evaluated the activation patterns of the NLRP3 inflammasome pathway in the renal tissues of LN patients. NLRP3 was extensively activated in various renal intrinsic cells and infiltrating cells, and was closely associated with disease activity, which needs further explorations."

07:35 EDT Anavex announces long term study results from ANAVEX 2-73-RS-001 study - Anavex Life Sciences announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate disease modifying effect of ANAVEX2-73 for adult patients with Rett syndrome. In the U.S. ANAVEX2-73-RS-001 trial, of all 25 patients who both started and completed the randomized, double-blind, placebo-controlled study. The effect of ANAVEX2-73 in the double-blind part of the U.S. ANAVEX2-73-RS-001 study was maintained in the open label 12-week extension study. Patients assigned first to ANAVEX2-73 in the double-blind part of the study and who continued on ANAVEX2-73 during the open label extension study had a statistically significant reduction in disease severity when compared with patients assigned first to placebo in the double-blind part of the study and who then received ANAVEX2-73 during the open label extension part of the study. Continued improvement from the drug, as measured with the Rett Syndrome Behavior Questionnaire total score, was observed from the start of the double-blind study to the end of the open label extension part for patients continuing on ANAVEX2-73. Patients previously on placebo, who switched to ANAVEX2-73 in the OLE part of the study experienced improvement during the OLE part. Additionally, disease progression, which is defined as change in Rett syndrome disease severity with time, was also reduced with long-term treatment with ANAVEX2-73. Patients assigned first to ANAVEX2-73 in the double-blind part of the study and who continued on ANAVEX(R)2-73 during the open label extension study had a statistically significant reduction in disease progression when compared with patients assigned first to placebo in the double-blind part of the study and who then received ANAVEX(R)2-73 during the open label extension part of the study. Patients assigned to ANAVEX2-73 at the start of the double-blind study experienced more benefit of drug effect than could be explained by symptomatic benefit alone - hence, ANAVEX2-73 exhibited both symptomatic and disease modifying effect. The reduction in annual rate of disease progression for those patients, who continued on ANAVEX2-73 was over 3-fold greater, relative to those who switched from placebo to ANAVEX2-73.

07:33 EDT Amesite announces V6.3 update with AI-first infrastructure - Amesite announced that V6.3 will be available to its Customers on July 10, 2023. By implementing Azure's cloud solutions, Amesite has enhanced its platform's efficiency and ensured secure authentication with Azure AD B2C. The incorporation of Azure's latest database technology enables Amesite to deliver services faster and improve user experiences. The centralization of Amesite's innovation deployments allows rapid access to new features such as games and other AI offerings.

07:32 EDT Canadian Pacific Kansas City issues multi-year guidance - As part of its 2023 Investor Day, Canadian Pacific Kansas City issued new multi-year guidance and unveiled the next chapter in its long-term growth strategy as the only single-line railroad that connects a continent. Financial targets over the period of 2024-2028: Revenue compound annual growth rate (CAGR) of high-single digits; Core adjusted diluted earnings per share (EPS) 1 CAGR of double-digits; Continued margin improvement through cost control and operating leverage; Capital expenditures of approximately $2.6 billion to $2.8 billion per year; Free cash conversion of Core adjusted income1 of approximately 90%; Return to double-digit Adjusted Return on Invested Capital.

07:16 EDT Laser Photonics launches e-commerce store - Laser Photonics (LASE) announced the launch of its e-commerce store leveraging Shopify (SHOP). LPC is bringing its technology to millions of daily Shopify users. The website will allow customers to purchase the miniGIANT as well as products from the Laser Photonics CleanTech and MarkStar lines. The e-commerce store will also enable customers to buy merchandise and accessories like laser safety barriers and goggles.

07:13 EDT Nasdaq welcomed 60 IPOs in 1H23 - Nasdaq announced that in 1H23, it welcomed 60 initial public offerings, raising a total of $3.71B. A total of 46 operating companies and 14 SPACs listed on Nasdaq during the first six months of 2023, representing an 88% win rate in the U.S. market, and extending Nasdaq's leadership to 38 consecutive quarters. In addition to the IPOs, 4 companies transferred their corporate listing to Nasdaq. Additionally, Roper Technologies announced their intention to transfer their corporate listing to Nasdaq, representing $48B in market cap.

07:11 EDT Solaris Resources reports assay results from Warintza Project - Solaris Resources reports assay results from a series of holes aimed at growing the 'Indicative Starter Pit' within the Warintza Central zone at its Warintza Project in southeastern Ecuador. Highlights: Mineral resource expansion drilling continues to target growth of the 'Indicative Starter Pit', an area of near surface, high-grade mineralization estimated at 180 Mt at 0.82% CuEq and 107 Mt at 0.73% CuEq in the Warintza Mineral Resource Estimate. Recent drilling has expanded the Northeast Extension zone to the north-northeast where further step-outs are planned, while a 250m step-out on the opposite side of Warintza Central has expanded the zone to the northwest and opened up new potential. SLS-72 was collared from a newly-constructed step out platform 200m to the northeast, returning 268m of 0.60% CuEq within a broader interval of 830m averaging 0.50% CuEq from 48m depth, extending the zone to the northeast where it remains open; SLS-71 was collared from the same platform within the northeast extension zone and drilled northwest into a partially open volume, returning 212m of 0.60% CuEq, including 50m of 0.87% CuEq, within a broader interval of 494m of 0.42% CuEq from near surface; SLS-73 was collared from another newly-constructed step out platform 250m to the north, returning 26m of 0.96% CuEq from near surface and 128m of 0.60% CuEq within a broader interval, extending the zone to the northeast where it remains open; These three holes expand the Northeast Extension zone to the east and northeast where two additional 200m step-out platforms have been planned for construction to test the potential extension of the zone beneath shallow saprolitic cover; On the opposite side of Warintza Central, SLS-74 was collared from a newly-constructed platform stepping out 250m to the northwest of the existing drill grid to test the potential extension of high grade, near surface mineralization - it returned 54m of 0.80% CuEq from surface within a broader interval of 224m of 0.41% CuEq; SLS-74 includes lower grade mineralization within a porphyritic granodiorite modelled as the northwestern contact of Warintza Central - ongoing mapping and sampling aims to assess the potential for better-developed mineralization higher up in this intrusive phase in the 700m gap to Warintza West; Additional assays are expected soon from drilling targeting further growth at Warintza East, follow-up drilling at the recent high-grade Warintza Southeast discovery and the new Patrimonio discovery.

07:10 EDT Perpetua and Iron Woman begin new round of cleanup at Stibnite Mining District - Perpetua Resources and Iron Woman Construction and Environmental Services successfully mobilized teams and equipment to site this week for the next round of voluntary legacy waste cleanup and water quality improvements in the historical Stibnite Mining District. This summer, Iron Woman has been engaged to help Perpetua Resources move more than 300,000 tons of legacy mine waste away from sensitive waterways on site and relocate it to areas where it can be more safely stored. Early mobilization included transporting dump trucks, loaders, office trailers, water tanks and reclamation supplies into Stibnite via Warm Lake Road and Johnson Creek Road. In accordance with Perpetua's transportation best practices, oversized loads and sensitive loads were escorted to site with pilot cars. Equipment will stay at Stibnite until early fall, when this phase of work is expected to be complete.

07:09 EDT GeneDx to present data on urine mitochondrial DNA testing - GeneDx will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023. "Mitochondrial disease may be caused by genetic variants in DNA found in the nucleus of cells or by genetic variants in the body's mitochondrial DNA. The m.3243Agreater thanG variant is found in the mitochondrial MT-TL1 gene and is the most common pathogenic mtDNA variant linked to conditions including mitochondrial encephalopathy, lactic acidosis, and stroke-like episode syndrome, maternally inherited diabetes and deafness, and mitochondrial myopathy," said Renkui Bai, M.D., Ph.D., FACMG, Director, Clinical Genetics at GeneDx. "To date, systemic evaluation of patient demographics, age of disease onset, and level of heteroplasmy in different tissue types has been challenging to report for patients with the m.3243Agreater thanG variant. Data presented this week by GeneDx demonstrates how urine mitochondrial DNA testing can be a clinically impactful and non-invasive option for analysis of the m.3243Agreater thanG variant."

07:08 EDT Roivant Sciences expects cash to fund operations into 2H25 - Roivant reported its consolidated cash, cash equivalents and restricted cash of $1.7B at March 31, 2023, supporting cash runway into the second half of calendar year 2025.

07:07 EDT Roivant Sciences announces upcoming milestones - Dermavant plans to submit its sNDA for VTAMA in atopic dermatitis to the FDA in the first quarter of calendar year 2024. Immunovant expects IMVT-1402 Phase 1 initial data from single-ascending dose cohorts in August/September 2023 and initial data from multiple-ascending dose cohorts in October/November 2023. Additionally, for batoclimab: top-line results from the ongoing myasthenia gravis trial are expected in the second half of calendar year 2024. Top-line results from the Phase 3 thyroid eye disease program, consisting of two Phase 3 clinical trials, are expected in the second half of calendar year 2025. Initial data from period 1 of the Phase 2B trial in chronic inflammatory demyelinating polyneuropathy is expected to be available in the first half of calendar year 2024. Initial results from the Phase 2 proof-of-concept trial in GD are expected in the fourth quarter of calendar year 2023. Telavant has initiated a Phase 2 dose-ranging study of RVT-3101 in Crohn's disease with data expected in the fourth quarter of calendar year 2024. Priovant plans to announce topline results from the potentially registrational trial evaluating brepocitinib for the treatment of patients with systemic lupus erythematosus in the fourth quarter of calendar year 2023. Priovant also expects to announce topline results from the Phase 3 trial in dermatomyositis in calendar year 2025. Hemavant plans to announce data from the ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk myelodysplastic syndromes patients in the second half of calendar year 2023. Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the second half of calendar year 2024.

07:05 EDT AerCap announces lease placment of three Embraer E195-E1 aircraft with Airlink - AerCap (AER) announced lease placements with Airlink, the largest regional airline in Southern Africa, for three used Embraer (ERJ) E195-E1 aircraft. The first aircraft was delivered in March, while the second and third aircraft are scheduled for delivery in July 2023.

07:04 EDT Cognition announces Phase 2 SEQUEL data not statistically significant - Cognition Therapeutics announced topline results from its Phase 2 double-blind, single-crossover SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease. The study, which was conducted in the Netherlands, met its primary endpoints for safety and tolerability and showed positive effects for CT1812-treated participants as measured via quantitative electroencephalogram. Research suggests that overall slowing of brain activity in Alzheimer's disease can be measured by an increase in relative theta power using qEEG and other measures of brain connectivity. The SEQUEL study examined brain wave changes over 4 weeks of treatment and showed that participants treated with CT1812 experienced a numerical reduction in relative theta power compared to the period when they were on placebo. While not statistically significant, these data indicate a positive impact on underlying brain function and are supported by nominally significant and directionally positive changes in AECc and alpha power. In addition to global measures of brain activity, this study assessed brainwave changes in frontal, central, temporal and posterior regions. Treatment with CT1812 was associated with decreases in relative theta in each of these regions, with statistical significance in the change in relative theta in the central region. In addition to changes in theta wave patterns, an AECc analysis of the qEEG results showed that CT1812 treatment was associated with nominally statistically significantly greater connectivity between brain regions. The brain's ability to communicate and exchange information between regions is critical to cognition.

07:03 EDT Canadian Pacific Kansas City, CSX, G&W to create new CPKC-CSX interchange - Canadian Pacific Kansas City (CP), CSX Corporation (CSX) and Genesee & Wyoming(G&W) announced they have reached agreements that when completed will create a new direct CPKC-CSX interchange connection in Alabama. As part of the series of proposed transactions, CPKC and CSX would each acquire or operate portions of Meridian & Bigbee Railroad, L.L.C., a G&W-owned railway in Mississippi and Alabama, to establish a new freight corridor for shippers that connects Mexico, Texas and the U.S. Southeast. Under the agreements announced today, CPKC would acquire and operate the segment of the MNBR between Meridian and Myrtlewood, Ala. and CSX would operate the lines currently leased by MNBR east of Myrtlewood. As a result, CPKC and CSX would establish a direct CPKC-CSX interchange at or near Myrtlewood, Ala. In exchange, G&W would acquire certain Canadian properties owned by CPKC and other rights. MNBR would receive rights to continue to provide local service to existing customers on former MNBR-owned lines and connect with other railroads without interchange restrictions. Terms of the transactions were not disclosed and will be addressed in definitive agreements that the parties have agreed to negotiate. Certain portions of the transactions are subject to regulatory review and approval from, or exemption by, the U.S. Surface Transportation Board.

07:01 EDT Innovative Eyewear announces new retail partnership with PRIVATO - Innovative Eyewear announced a new retail partnership with PRIVATO Duty Free, a provider of travel luxury goods. As part of the partnership, PRIVATO will be creating a Lucyd Eyewear retail showcase in seven of the company's airport-based locations, featuring a number of Lucyd styles and the company's new modular LCD retail display that acts as an always-on, automated salesperson for Lucyd Eyewear. We anticipate the complete roll-out in Q3.

06:51 EDT Eton Pharmaceuticals receives CRL from FDA for dehydrated alcohol injection - Eton Pharmaceuticals announced that the U.S. FDA issued a Complete Response Letter in response to its New Drug Application for dehydrated alcohol injection for the treatment of methanol poisoning. The issues raised in the CRL relate primarily to Chemistry Manufacturing and Controls. The company believes all issues in the CRL are addressable and will develop a comprehensive action plan to address the FDA's concerns. "While we are disappointed with the FDA's decision, our commercial business remains strong, and we are pleased that our momentum in product revenue growth has continued. We expect to once again report record product revenue in the second quarter of 2023. With the recent addition of Betaine Anhydrous for Oral Solution to our commercial product portfolio, we are well positioned for continued sustainable long-term growth," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

06:46 EDT Spire Global sings agreement with OroraTech for eight-satellite constellation - Spire Global has signed an agreement with OroraTech, the global leader in space-based thermal intelligence, to build, launch and operate an eight-satellite constellation dedicated to global temperature monitoring. Once operational, it will represent the first and largest constellation of satellites dedicated to tracking and monitoring wildfires. Each spacecraft in the eight-satellite constellation, which will be launched in mid-2024, will carry OroraTech's proprietary thermal-infrared optical payload and data processing unit with on-orbit fire detection capability. The urgent data collected by the satellites will be downlinked via Spire's ground station network and delivered to OroraTech through an API. The satellites will help identify and monitor areas at risk of wildfires as well as enable early detection of wildfire hot spots, which are increasing rapidly as a result of climate change.

06:16 EDT Terra Property Trust, Western Asset Mortgage to combine - Terra Property Trust and Western Asset Mortgage jointly announced that they have entered into a definitive merger agreement under which TPT and WMC have agreed to combine to form a REIT that is expected to have approximately $1.2B in assets and $436M of adjusted book value upon completion of the merger. Under the terms of the agreement, WMC will issue to TPT stockholders newly designated shares of WMC Class B common stock as merger consideration. The number of shares of WMC Class B common stock to be received by TPT stockholders will be based on an exchange ratio to be determined by dividing TPT's adjusted book value per share by WMC's adjusted book value per share, calculated pursuant to the terms of the agreement. Under the agreement, the book values of each company will reflect certain agreed adjustments; TPT's book value will include accumulated depreciation and amortization on real estate assets owned, and WMC's will reflect the deconsolidation of variable interest entities. For illustrative purposes, as of March 31, WMC's and TPT's adjusted book values per share would have been $17.30 and $13.58, respectively, with every TPT share being exchanged on a pro forma basis for 0.785 WMC shares. This would value WMC at 100% of its adjusted book value of approximately $106M as of March 31, as compared to WMC's market capitalization of approximately $56M based on the closing price of WMC's common stock on June 27. The newly issued WMC Class B common shares will have dividend, distribution, and other rights identical to those of WMC's Class A common shares, except that the newly issued WMC Class B common stock will not be listed on the New York Stock Exchange but will automatically convert into an equal number of shares of WMC Class A common stock in one-third increments on the 6-, 12-, and 18-month anniversaries of the completion of the merger. WMC's stockholders will retain their existing shares, which will be reclassified as Class A common stock at the effective time of the merger and continue to be listed on the New York Stock Exchange under a new name. Upon the closing of the merger, TPT stockholders are expected to own approximately 76% of the combined company's outstanding common stock, while WMC stockholders are expected to own approximately 24%. A subsidiary of Mavik Capital Management, the external manager of TPT, has committed to use reasonable best efforts to purchase or cause a third party to purchase shares of WMC Class A common stock with an aggregate purchase price of up to $4M after the closing and prior to the three-month anniversary of the completion of the merger to support the combined company's common stock trading level, subject to the terms of the equity support agreement. The transaction has been unanimously approved by each of the boards of directors of TPT and WMC. The transaction is expected to close during the fourth quarter of 2023, subject to the respective approvals by the stockholders of TPT and WMC and other customary closing conditions. WMC has entered into a voting agreement with key stockholders of TPT under which such stockholders have committed to vote in favor of the transaction, subject to the terms and conditions of the voting agreement.

06:05 EDT KBR teams with McCallie Associates, awarded $300M NASA contract - KBR announced it is a subcontractor to McCallie Associates, a certified small business selected to provide mission and instrument systems engineering services at NASA's Goddard Space Flight Center, or GSFC, in Maryland and Wallops Flight Facility in Virginia. The Systems Engineering Advanced Services II, or SEAS II, contract has a five-year period of performance with a total value of $300M. SEAS II supports NASA's Mission Engineering and Systems Analysis Division and related Applied Engineering and Technology Directorate organizations.

06:02 EDT Western Asset Mortgage, Terra Property Trust to merge - Terra Property Trust and Western Asset Mortgage Capital jointly announced that they have entered into a definitive merger agreement under which TPT and WMC have agreed to combine to form a REIT that is expected to have approximately $1.2B in assets and $436M of adjusted book value upon completion of the merger. Under the terms of the Agreement, WMC will issue to TPT stockholders newly designated shares of WMC Class B common stock as merger consideration. The number of shares of WMC Class B common stock to be received by TPT stockholders will be based on an exchange ratio to be determined by dividing TPT's adjusted book value per share by WMC's adjusted book value per share, calculated pursuant to the terms of the Agreement. Under the Agreement, the book values of each company will reflect certain agreed adjustments; TPT's book value will include accumulated depreciation and amortization on real estate assets owned, and WMC's will reflect the deconsolidation of variable interest entities. For illustrative purposes, as of March 31, 2023, WMC's and TPT's adjusted book values per share would have been $17.30 and $13.58, respectively, with every TPT share being exchanged on a pro forma basis for 0.785 WMC shares. This would value WMC at 100% of its adjusted book value (prior to deducting transaction expenses) of approximately $106 million as of March 31, 2023, as compared to WMC's market capitalization of approximately $56 million based on the closing price of WMC's common stock on June 27, 2023. The newly issued WMC Class B common shares will have dividend, distribution, and other rights identical to those of WMC's Class A common shares, except that the newly issued WMC Class B common stock will not be listed on the New York Stock Exchange but will automatically convert into an equal number of shares of WMC Class A common stock in one-third increments on the 6-, 12-, and 18-month anniversaries of the completion of the merger. WMC's stockholders will retain their existing shares, which will be reclassified as Class A common stock at the effective time of the merger and continue to be listed on the New York Stock Exchange under a new name. Upon the closing of the merger, TPT stockholders are expected to own approximately 76% of the combined company's outstanding common stock, while WMC stockholders are expected to own approximately 24%. A subsidiary of Mavik Capital Management, LP, the external manager of TPT, has committed to use reasonable best efforts to purchase or cause a third party to purchase shares of WMC Class A common stock with an aggregate purchase price of up to $4.0 million after the closing and prior to the three-month anniversary of the completion of the merger to support the combined company's common stock trading level, subject to the terms of the equity support agreement. The transaction has been unanimously approved by each of the Boards of Directors of TPT and WMC. The transaction is expected to close during the fourth quarter of 2023, subject to the respective approvals by the stockholders of TPT and WMC and other customary closing conditions. WMC has entered into a voting agreement with key stockholders of TPT under which such stockholders have committed to vote in favor of the transaction, subject to the terms and conditions of the voting agreement.

05:25 EDT DraftKings no longer pursuing PointsBet U.S. acquisition - DraftKings (DKNG) announced that the company is no longer pursuing the acquisition of the U.S. business of PointsBet (PBTHF).

05:20 EDT Jacobs, Mace JV to deliver green urban infrastructure program in Greece - The joint venture of Mace and Jacobs, appointed by Hellinikon S.M.S.A., a subsidiary of LAMDA Development S.A., is Program Management Consultant for the Ellinikon development and has Project Management responsibilities for the four primary building projects within the scheme - Riviera Tower, Vouliagmenis Mall Complex, Riviera Galleria and the Mixed Use Tower.